SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH LISTED COMPANY


Any AUS or NZ company

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

RECCE PHARMACEUTICALS LTD(RCE)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
RECCE PHARMACEUTICALS LTD17/01/2018
RECCE LIMITED17/01/2018

Shareholder links

Our website ranking of RCE: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Registry Services LEVEL 2, 267 St Georges Terrace,, PERTH, WA, AUSTRALIA, 6000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000RCE5
Address: Suite 3, 3 Brodie Hall Drive Technology Park BENTLEY, WA 6102 AUSTRALIA
Tel:  +61 (8) 9253 9800 Fax: +61 (8) 9253 9899

Date first listed: 15/01/2016
Company Secretary: Alistair McKeough
Sector: Pharmaceuticals Biotechnology & Life Sciences Industry Group: 
Activities: Pharmaceutical research and development

News & Events

Expand this box to read and print

The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately, following the release by RCE of an announcement regarding anti-viral testing results.

10/11/2020

RECCE 327, a synthetic anti-infective showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virus. This showed encouraging inhibition and is advancing to Stage 1b (confirmatory in vitro testing and a cytotoxicity assessment), underway in near weeks. U.S. in-vivo studies running in parallel are on track for data CY2020.

10/11/2020

The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Wednesday, 11 November 2020 or the release of an announcement by the Company in relation to the results.

10/11/2020

The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Tuesday, 10 November 2020 or the release of an announcement by the Company in relation to the results.

09/11/2020

The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement relating to anti-viral testing results.

05/11/2020

The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding a material research agreement.

08/07/2020

RECCE 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively). Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute. Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections.

08/07/2020

The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding a material research agreement.

08/07/2020

name changed from Recce Limited

17/01/2018
OFX Transferring Money Internationally to Free

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

They're registered on Automic not Computershare

30/04/2020 13:24:35

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    08/08/2019Michele Dilizia-45,000$0.222$9,975
    07/08/2019Michele Dilizia-277,000$0.217$60,180
    06/03/2019James Graham650,000$0.155$100,490
    09/03/2017James Graham-79,960$0.250$19,956
    12/09/2016Bernadette Murdoch20,000$0.250$5,000

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    John PrendergastChairman, Independent Director24/04/2018
    Justin ReynoldsCFO29/11/2017
    Alan DuntonIndependent Director14/07/2020
    Dongke ZhangNon Exec Director15/01/2016
    Ian BrownNon Exec Director15/01/2016
    Michele DiliziaExecutive Director15/01/2016
    James GrahamExecutive Director, CEO15/01/2016
    Justin WardExecutive Director09/07/2019

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Graham MelroseExecutive Director15/01/201603/07/2020
    Peter WilliamsCFO15/01/201629/11/2017
    Dominic BarnesIndependent Director16/05/201621/01/2017
    Bernadette MurdochIndependent Director27/05/201622/11/2016

    Date of first appointment, title may have changed.